CELZ Stock Catalyst: Creative Medical Technology Holdings Granted U.S. Patent for Exosome-Based Immunotherapy for Type 1 Diabetes

Aug 6, 2026 · 4:02am ET

The company received a Notice of Allowance for the new patent.

Max move

+101.4%

High of day $1.75

Sparker timei

4:02am ET

CELZ · Aug 6, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering its Exosome-Based Immunotherapy for Type 1 Diabetes. The patent approval signifies a significant advancement in the company's biotechnology portfolio.

The new patent will provide Creative Medical Technology Holdings with exclusive rights to the innovative immunotherapy, enhancing its competitive position in the biotechnology sector. The company's free float stands at 2,384,644 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time CELZ sparks.

Download Sniper App →

Catch the next CELZ-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →